|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahmed S, Johnson K, Ahmed O and Iqbal N:
Advances in the management of colorectal cancer: From biology to
treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Rosa M, Pace U, Rega D, Costabile V,
Duraturo F, Izzo P and Delrio P: Genetics, diagnosis and management
of colorectal cancer (Review). Oncol Rep. 34:1087–1096.
2015.PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Macedo MP, Andrade LB, Coudry R, Crespo R,
Gomes M, Lisboa BC, Aguiar S Jr, Soares FA, Carraro DM and Cunha
IW: Multiple mutations in the Kras gene in colorectal cancer:
Review of the literature with two case reports. Int J Colorectal
Dis. 26:1241–1248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar
|
|
10
|
Inoue Y, Saigusa S, Iwata T, Okugawa Y,
Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The
prognostic value of KRAS mutations in patients with colorectal
cancer. Oncol Rep. 28:1579–1584. 2012.PubMed/NCBI
|
|
11
|
Arrington AK, Heinrich EL, Lee W, Duldulao
M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J: Prognostic and
predictive roles of KRAS mutation in colorectal cancer. Int J Mol
Sci. 13:12153–12168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kadowaki S, Kakuta M, Takahashi S,
Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K,
Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in
curatively resected colorectal cancer. World J Gastroenterol.
21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sameen S, Barbuti R, Milazzo P, Cerone A,
Del Re M and Danesi R: Mathematical modeling of drug resistance due
to KRAS mutation in colorectal cancer. J Theor Biol. 389:263–273.
2016. View Article : Google Scholar
|
|
14
|
Collin M, Dickinson R and Bigley V:
Haematopoietic and immune defects associated with GATA2 mutation.
Br J Haematol. 169:173–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai FY and Orkin SH: Transcription factor
GATA-2 is required for proliferation/survival of early
hematopoietic cells and mast cell formation, but not for erythroid
and myeloid terminal differentiation. Blood. 89:3636–3643.
1997.PubMed/NCBI
|
|
16
|
Ohmori S, Moriguchi T, Noguchi Y, Ikeda M,
Kobayashi K, Tomaru N, Ishijima Y, Ohneda O, Yamamoto M and Ohneda
K: GATA2 is critical for the maintenance of cellular identity in
differentiated mast cells derived from mouse bone marrow. Blood.
125:3306–3315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nandakumar SK, Johnson K, Throm SL,
Pestina TI, Neale G and Persons DA: Low-level GATA2 overexpression
promotes myeloid progenitor self-renewal and blocks lymphoid
differentiation in mice. Exp Hematol. 43:565–577. e1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu AP, McReynolds LJ and Holland SM:
GATA2 deficiency. Curr Opin Allergy Clin Immunol. 15:104–109. 2015.
View Article : Google Scholar :
|
|
19
|
Vicente C, Conchillo A, García-Sánchez MA
and Odero MD: The role of the GATA2 transcription factor in normal
and malignant hematopoiesis. Crit Rev Oncol Hematol. 82:1–17. 2012.
View Article : Google Scholar
|
|
20
|
Wang Y, He X, Ngeow J and Eng C: GATA2
negatively regulates PTEN by preventing nuclear translocation of
androgen receptor and by androgen-independent suppression of PTEN
transcription in breast cancer. Hum Mol Genet. 21:569–576. 2012.
View Article : Google Scholar
|
|
21
|
Vidal SJ, Rodriguez-Bravo V, Quinn SA,
Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la
Iglesia-Vicente J, Lee A, Readhead B, et al: A targetable
GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
Cancer Cell. 27:223–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q,
Grenade C, Ke J, Zhang C, Chen H, et al: Three-tiered role of the
pioneer factor GATA2 in promoting androgen-dependent gene
expression in prostate cancer. Nucleic Acids Res. 42:3607–3622.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang
H, Xing J, Zhang C, Yao Z, Zhang N, et al: Expression and
prognostic significance of GATA-binding protein 2 in colorectal
cancer. Med Oncol. 30:4982013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kumar MS, Hancock DC, Molina-Arcas M,
Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E,
Lassailly F, Matthews N, Nye E, et al: The GATA2 transcriptional
network is requisite for RAS oncogene-driven non-small cell lung
cancer. Cell. 149:642–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen S, Mao CQ, Yang XZ, Du XJ, Liu Y, Zhu
YH and Wang J: Cationic lipid-assisted polymeric nanoparticle
mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS
mutant non-small-cell lung carcinoma. Mol Pharm. 11:2612–2622.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao J, Li YY, Sun PN and Shen L:
Comparative analysis of dideoxy sequencing, the KRAS StripAssay and
pyrosequencing for detection of KRAS mutation. World J
Gastroenterol. 16:4858–4864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xing X, Peng L, Qu L, Ren T, Dong B, Su X
and Shou C: Prognostic value of PRL-3 overexpression in early
stages of colonic cancer. Histopathology. 54:309–318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ayanbule F, Belaguli NS and Berger DH:
GATA factors in gastrointestinal malignancy. World J Surg.
35:1757–1765. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peters I, Dubrowinskaja N, Tezval H,
Kramer MW, von Klot CA, Hennenlotter J, Stenzl A, Scherer R, Kuczyk
MA and Serth J: Decreased mRNA expression of GATA1 and GATA2 is
associated with tumor aggressiveness and poor outcome in clear cell
renal cell carcinoma. Target Oncol. 10:267–275. 2015. View Article : Google Scholar
|
|
30
|
Li YW, Wang JX, Yin X, Qiu SJ, Wu H, Liao
R, Yi Y, Xiao YS, Zhou J, Zhang BH, et al: Decreased expression of
GATA2 promoted proliferation, migration and invasion of HepG2 in
vitro and correlated with poor prognosis of hepatocellular
carcinoma. PLoS One. 9:e875052014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tessema M, Yingling CM, Snider AM, Do K,
Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, et al: GATA2
is epigenetically repressed in human and mouse lung tumors and is
not requisite for survival of KRAS mutant lung cancer. J Thorac
Oncol. 9:784–793. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Darnell JE Jr: Transcription factors as
targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SE, Paik HY, Yoon H, Lee JE, Kim N and
Sung MK: Sex- and gender-specific disparities in colorectal cancer
risk. World J Gastroenterol. 21:5167–5175. 2015. View Article : Google Scholar : PubMed/NCBI
|
